Nerve growth factor concentrations in the synovial fluid from healthy dogs and dogs with secondary osteoarthritis

@article{Isola2011NerveGF,
  title={Nerve growth factor concentrations in the synovial fluid from healthy dogs and dogs with secondary osteoarthritis},
  author={Maurizio Isola and Vanni Ferrari and Alda Miolo and Fabio Stabile and Daniele Bernardini and Paolo Carnier and Roberto Busetto},
  journal={Veterinary and Comparative Orthopaedics and Traumatology},
  year={2011},
  volume={24},
  pages={279 - 284}
}
Summary Objective: To measure the concentrations of nerve growth factor (NGF) in the synovial fluid from normal dogs and dogs with osteoarthritis (OA) secondary to common joint disorders. Methods: Nerve growth factor synovial concentrations were measured by ELISA assay in 50 dogs divided into three groups: 12 healthy, 16 affected by acute lameness within seven days before enrolment, and 22 with chronic lameness persisting by more than one month before enrolment and accompanied by radiological… 

Nerve growth factor in the equine joint.

Synovial fluid D-dimer concentration in horses with osteochondritis dissecans and osteoarthritis

Activation of coagulation and fibrinolysis play a role in the pathophysiology of equine OCD and OA and no statistical differences were observed when comparing synovial D-dimer concentrations from the OCD horses with the OA-affected horses.

Canine Brief Pain Inventory scores for dogs with osteoarthritis before and after administration of a monoclonal antibody against nerve growth factor.

Results of this study suggested the evaluated anti-NGF mAb decreased PS and PI scores for 4 weeks after administration, and may be effective for alleviation of signs of pain in dogs with osteoarthritis for up to 4 weeks.

Measurements of C-reactive protein (CRP) and nerve-growth-factor (NGF) concentrations in serum and urine samples of dogs with neurologic disorders

It is concluded that neither CRP nor NGF in urine or serum can be considered as reliable biomarkers for micturition disorders in dogs with spinal cord disorders in a clinical setting, but their production might be part of the pathogenesis of such disorders.

Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats

The mechanism of action of NGF, the role of N GF in osteoarthritis, research in rodent OA models and the current status of the development of anti-NGF mAbs in humans are outlined.

Estrogen Regulation of the Expression of Pain Factor NGF in Rat Chondrocytes

It was shown that E2 reduces chondrocytes NGF expression significantly, even after stimulation by TGF-β1 or IL-1β, and MEK-ERK signaling is involved in this process.

The Pathobiology of the Meniscus: A Comparison Between the Human and Dog

The aims of this review are to provide an overview of the anatomy, physiology, and pathology of the human and canine meniscus, to compare the known signaling pathways involved in spontaneous menISCus pathology between both species, and to assess the relevance of dogs with spontaneous meniscal pathology as a translational model.

References

SHOWING 1-10 OF 43 REFERENCES

Elevated Nerve Growth Factor Levels in the Synovial Fluid of Patients with Inflammatory Joint Disease

The NGF concentrations were significantly higher in the synovial fluids from both inflamed groups (ANOVA p < 0.05) compared to normals, suggesting raised levels of NGF insynovial fluid may contribute directly to joint inflammation via activation of inflammatory cells.

Nerve growth factor (NGF) autoantibodies and NGF in the synovial fluid: implications in spondylarthropathies.

A role of NGF autoantibodies and NGF in joint inflammation especially in spondylarthropathies is suggested.

Nerve growth factor and receptor expression in rheumatoid arthritis and spondyloarthritis

The presence of neurotrophins as well as their receptors, in particular the NGF/trkA-p75 axis in peripheral synovitis warrants further functional investigation of their active involvement in chronic inflammatory arthritis.

The regulatory role of nerve growth factor and its receptor system in fibroblast‐like synovial cells

The increased NGF level in SF of inflammatory arthritis suggest that there is cross‐talk between NGF/NGF‐R and FLS, and results suggest that dysregulated production of NGF may lead to synovial cell proliferation and thus could influence the inflammatory and proliferative cascades ofinflammatory arthritis.

Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment

NTs and their receptors are expressed in inflamed peripheral joints of patients with spondyloarthritis and they may be involved in the local disease processes.

Nerve growth factor in the synovial fluid of patients with chronic arthritis.

NGF was present in the synovial fluid and synovium of patients with chronic arthritis, but was undetectable in control fluids, suggesting that NGF might be involved in the pathogenesis of arthritis.

Nerve growth factor in rheumatic diseases.

Increased expression of nerve growth factor (NGF) and high affinity NGF receptor (p140 TrkA) in human osteoarthritic chondrocytes.

This is the first study showing that human chondrocytes synthesize NFG-beta and express on their surface the high affinity NGFR (p140 TrkA) in the osteoarthritic process, suggesting a role of NGF in the pathophysiology of OA.

Nerve growth factor release by human synovial fibroblasts prior to and following exposure to tumor necrosis factor-alpha, interleukin-1 beta and cholecystokinin-8: the possible role of NGF in the inflammatory response.

NGF is produced and released and TrkA receptors are expressed in synovial inflammation, involved in the modulation rather than in the induction of the joint inflammatory response.